CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders

References

• World Health Organization WHO. Geneva, Switzerland: WHO Media center. Available from: https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorders. Accessed May 19, 2022.
   Google Scholar
• Loomes R, Hull L, Mandy WPL. What is the male-to-female ratio in autism spectrum disorder? A systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2017;56(6):466–474. doi:10.1016/j.jaac.2017.03.013
   PubMed Web of Science ®Google Scholar
• Hervas A. Un autismo, varios autismos. Variabilidad fenotipica en los trastornos del espectro autista [One autism, several autisms. Phenotypical variability in autism spectrum disorders]. Rev Neurol. 2016;62(Suppl 1):S9–S14.
   PubMedGoogle Scholar
• Sharma SR, Gonda X, Tarazi FI. Autism spectrum disorder: classification, diagnosis and therapy. Pharmacol Ther. 2018;190:91–104. doi:10.1016/j.pharmthera.2018.05.007
   PubMed Web of Science ®Google Scholar
• Brown JT, Eum S, Cook EH, Bishop JR. Pharmacogenomics of autism spectrum disorder. Pharmacogenomics. 2017;18(4):403–414. doi:10.2217/pgs-2016-0167
   PubMed Web of Science ®Google Scholar
• Antshel KM, Russo N. Autism spectrum disorders and ADHD: overlapping phenomenology, diagnostic issues, and treatment considerations. Curr Psychiatry Rep. 2019;21(5):34. doi:10.1007/s11920-019-1020-5
   PubMed Web of Science ®Google Scholar
• Sturman N, Deckx L, van Driel ML. Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database Syst Rev. 2017;11(11):CD011144. doi:10.1002/14651858.CD011144.pub2
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266–1274. doi:10.1001/archpsyc.62.11.1266.
   PubMed Web of Science ®Google Scholar
• Arranz MJ, Perez-Blanco J, Arias B. Pharmacogenetics of the efficacy of antipsychotic drugs in Schizophrenia. In: Rybakowski J, Serretti A, editors. Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders. Switzerland: Adis; 2016.
   Google Scholar
• Fabbri C, Di Girolamo G, Serretti A Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(6):487–520. doi:10.1002/ajmg.b.32184
   PubMed Web of Science ®Google Scholar
• Stevens T, Sangkuhl K, Brown JT, Altman RB, Klein TE PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2019;29(6):136–154. doi:10.1097/FPC.0000000000000376
   PubMed Web of Science ®Google Scholar
• Gomez-Sanchez CI, Carballo JJ, Riveiro-Alvarez R, et al. Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects. Sci Rep. 2017;7(1):10391.doi:10.1038/s41598-017-10912-y
   PubMed Web of Science ®Google Scholar
• Joensen B, Meyer M, Aagaard L Specific genes associated with adverse events of methylphenidate use in the pediatric population: a systematic literature review. J Res Pharm Pract. 2017;6(2):65–72. doi:10.4103/jrpp.JRPP_16_161
   PubMed Web of Science ®Google Scholar
• Stein MA, Waldman I, Newcorn J, Bishop J, Kittles R, Cook EH Jr. Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24(5):238–244. doi:10.1089/cap.2013.0102
   PubMed Web of Science ®Google Scholar
• Angyal N, Horvath EZ, Tarnok Z, et al. Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients. Prog Neuropsychopharmacol Biol Psychiatry. 2018;84(Pt A):122–128. doi:10.1016/j.pnpbp.2018.01.013
   PubMed Web of Science ®Google Scholar
• Marshe VS, Maciukiewicz M, Rej S, et al. Norepinephrine transporter gene variants and remission from depression with venlafaxine treatment in older adults. Am J Psychiatry. 2017;174(5):468–475. doi:10.1176/appi.ajp.2016.16050617
   PubMed Web of Science ®Google Scholar
• Thakur GA, Sengupta SM, Grizenko N, Choudhry Z, Joober R. Comprehensive phenotype/genotype analyses of the norepinephrine transporter gene (SLC6A2) in ADHD: relation to maternal smoking during pregnancy. PLoS One. 2012;7(11):e49616. doi:10.1371/journal.pone.0049616
   PubMed Web of Science ®Google Scholar
• Song J, Kim SW, Hong HJ, et al. Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder. Clin Neuropharmacol. 2014;37(5):136–141. doi:10.1097/WNF.0000000000000045
   PubMed Web of Science ®Google Scholar
• Park S, Kim JW, Yang YH, et al. Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder. Behav Brain Funct. 2012;8:22. doi:10.1186/1744-9081-8-22
   PubMed Web of Science ®Google Scholar
• Song J, Song DH, Jhung K, Cheon KA. Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder. Int Clin Psychopharmacol. 2011;26(2):107–113. doi:10.1097/YIC.0b013e32834152d1
   PubMed Web of Science ®Google Scholar
• Myer NM, Boland JR, Faraone SV. Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry. 2018;23(9):1929–1936. doi:10.1038/mp.2017.234
   PubMed Web of Science ®Google Scholar
• Yang L, Wang YF, Li J, Faraone SV. Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1154–1158. doi:10.1097/01.chi.0000131134.63368.46
   PubMed Web of Science ®Google Scholar
• Sun Z, Murry DJ, Sanghani SP, et al. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004;310(2):469–476. doi:10.1124/jpet.104.067116
   PubMed Web of Science ®Google Scholar
• Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008;30(7):454–460. doi:10.1016/j.braindev.2007.12.007
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, Huddart R, Gong L, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563–572. doi:10.1002/cpt.2350
   PubMed Web of Science ®Google Scholar
• Stage C, Dalhoff K, Rasmussen HB, et al. The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios. Basic Clin Pharmacol Toxicol. 2019;125(1):54–61. doi:10.1111/bcpt.13212
   PubMed Web of Science ®Google Scholar
• Zhao Z, Li X, Sun S, et al. Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis. Eur J Clin Pharmacol. 2016;72(10):1195–1204. doi:10.1007/s00228-016-2094-1
   PubMed Web of Science ®Google Scholar
• Xiao FY, Luo JQ, Liu M, et al. Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients. Sci Rep. 2017;7(1):7244. doi:10.1038/s41598-017-07736-1
   PubMed Web of Science ®Google Scholar
• Dimatteo C, D’Andrea G, Vecchione G, et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016;144:1–5. doi:10.1016/j.thromres.2016.05.025
   PubMed Web of Science ®Google Scholar
• Johnson KA, Barry E, Lambert D, et al. Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene. J Child Adolesc Psychopharmacol. 2013;23(10):655–664. doi:10.1089/cap.2013.0032
   PubMed Web of Science ®Google Scholar
• Labriet A, Lévesque É, De Mattia E, et al. Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. Pharmacogenomics. 2019;20(17):1179–1187. doi:10.2217/pgs-2019-0091
   PubMed Web of Science ®Google Scholar
• Yang L, Qian Q, Liu L, Li H, Faraone SV, Wang Y. Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children. J Neural Transm. 2013;120(7):1127–1133. doi:10.1007/s00702-012-0955-z
   PubMed Web of Science ®Google Scholar
• Vizeli P, Meyer Zu Schwabedissen HE, Liechti ME. No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA. Eur J Clin Pharmacol. 2018;74(3):275–283. doi:10.1007/s00228-017-2392-2
   PubMed Web of Science ®Google Scholar
• Hervas A, Serra-LLovich A, Rueda I, et al. Pharmacogenetic influences on the response to pharmacological treatment in autism spectrum disorders. J Transl Genet Genom. 2021;5:278–287. doi:10.20517/jtgg.2021.25
   Google Scholar
• Bruxel EM, Salatino-Oliveira A, Genro JP, et al. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics J. 2013;13(5):476–480. doi:10.1038/tpj.2012.25
   PubMed Web of Science ®Google Scholar
• Nemoda Z, Angyal N, Tarnok Z, Gadoros J, Sasvari-Szekely M. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology. 2009;57(7–8):731–733. doi:10.1016/j.neuropharm.2009.08.014
   PubMed Web of Science ®Google Scholar